Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy

► Several aglycosylated IgGs have been developed and are in clinical trials. ► Aglycosylated antibodies can be produced with high yields in bacteria. ► Aglycosylated antibody expression eliminates glycan heterogeneity. ► Engineered aglycosylated antibodies can display novel therapeutic effector functions.